Equities
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

  • Revenue in USD (TTM)5.40bn
  • Net income in USD1.49bn
  • Incorporated1994
  • Employees10.60k
  • Location
    Resmed Inc9001 Spectrum Center BlvdSAN DIEGO 92123-1438United StatesUSA
  • Phone+1 (858) 746-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.resmed.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RMD:NYQ since
announced
Transaction
value
VirtuOx IncDeal completed01 May 202501 May 2025Deal completed6.75%--
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zimmer Biomet Holdings Inc8.23bn705.00m19.11bn17.00k27.201.5010.632.323.553.5541.4264.110.37031.105.17--3.173.033.583.4669.7171.018.569.101.104.740.371829.107.206.08-21.98--9.260.00
Steris PLC5.83bn708.66m24.36bn17.79k34.563.4120.354.187.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.52bn720.70m26.95bn10.30k39.5910.0227.925.971.771.7711.086.990.65193.024.28438,436.9010.408.7916.4111.7560.2064.9715.9614.901.38--0.47850.0011.3422.276.4141.6314.79--
Veeva Systems Inc3.08bn860.33m28.62bn7.29k33.874.0631.809.295.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Waters Corp3.17bn642.63m31.72bn7.60k30.0412.3837.3510.0210.7710.7753.0326.110.65692.464.05--13.3417.0314.5320.6859.2859.0120.3022.40--16.770.3546--6.996.000.75184.26-8.14--
Agilent Technologies Inc6.95bn1.30bn35.58bn18.10k27.565.2822.375.124.564.5624.3423.820.56553.294.94383,867.4010.6111.4412.8213.6752.7353.2518.7518.821.5218.300.332220.766.735.411.0912.6327.887.10
GE HealthCare Technologies Inc20.63bn2.09bn36.61bn54.00k17.653.5313.401.784.554.5545.0322.770.58935.934.31381,944.406.156.708.469.2539.9840.4410.4410.491.139.970.48661.854.843.744.570.755813.23--
Resmed Inc5.40bn1.49bn36.79bn10.60k24.965.8221.766.8210.1210.1236.7543.390.69012.345.53509,256.5019.0015.3321.9417.7660.8557.2927.5321.962.32--0.09528.949.8411.7237.2017.64-1.021.69
Edwards Lifesciences Corp6.07bn1.06bn44.03bn15.80k42.00--39.827.261.811.8310.36------------------78.0179.3917.4024.79--------11.556.70-24.335.18----
Becton Dickinson and Co21.92bn1.76bn50.08bn72.00k28.751.9811.852.286.126.1276.3488.790.40042.968.52304,500.003.213.003.783.4846.4245.588.018.200.58266.680.435966.898.246.32-1.5846.93-0.23525.65
IDEXX Laboratories Inc4.30bn1.06bn50.25bn11.00k48.12--54.7611.6813.0813.0853.12--------391,245.60--28.96--43.5861.8060.3024.6222.86--37.95----10.429.7219.3312.742.94--
Data as of Feb 13 2026. Currency figures normalised to Resmed Inc's reporting currency: US Dollar USD

Institutional shareholders

32.87%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202517.44m11.95%
BlackRock Fund Advisorsas of 31 Dec 20258.74m5.99%
SSgA Funds Management, Inc.as of 31 Dec 20256.63m4.54%
Geode Capital Management LLCas of 31 Dec 20254.30m2.95%
Walter Scott & Partners Ltd.as of 31 Dec 20253.91m2.68%
Morgan Stanley & Co. LLCas of 31 Dec 20251.58m1.08%
First Trust Advisors LPas of 31 Dec 20251.52m1.04%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20251.38m0.95%
Invesco Capital Management LLCas of 30 Sep 20251.31m0.90%
BlackRock Advisors (UK) Ltd.as of 31 Dec 20251.17m0.80%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.